Table 3 Comparison of the background data of the cases and controls
Cases | Controls | p value | |
|---|---|---|---|
Age (years) (IQR) | 63(59–73) | 63(59–69) | 0.7224 |
Gender (female:male) | 35:4 | 99:7 | 0.4614 |
Disease dutaion (years) (IQR) | 15(12–30) | 15(11–22) | 0.52 |
Arthroplastic surgery (%) | 41 | 31 | 0.1527 |
Tender joint count (IQR) | 3(1–10) | 1(0–4) | 0.0087 |
Swollen joint count (IQR) | 2(0–4) | 1(0–3) | 0.1389 |
MHAQ (IQR) | 1.13(0.75-1.88) | 0.5(0.1-1) | 0.0001 |
CRP (mg/dl) (IQR) | 1.5(0.26-3.05) | 0.36(0.13-1.06) | 0.0023 |
ESR (mm/h) (IQR) | 46(21–70) | 33(20.5-57.5) | 0.1948 |
DAS28-CRP (IQR) | 3.63(2.60-4.68) | 2.81(2.01-3.43) | 0.0012 |
Stage1 (%) | 5.3 | 6.5 | |
Stage2 (%) | 13.2 | 19.6 | |
Stage3 (%) | 18.4 | 19.6 | |
Stage4 (%) | 63.1 | 54.3 | 0.7823 |
Class1 (%) | 7.9 | 20.4 | |
Class2 (%) | 47.3 | 58.1 | |
Class3 (%) | 39.5 | 18.3 | |
Class4 (%) | 5.3 | 3.2 | 0.0395 |
PtPainVAS (IQR) | 3.9(1.8-6.4) | 3(1.2-5) | 0.0937 |
PtGVAS (IQR) | 4.9(2–6.8) | 2.9(1.2-5) | 0.0314 |
DrGVAS (IQR) | 3.4(1.4-5.1) | 1.6(1–3.1) | 0.0121 |
Use of MTX (%) | 13 | 40 | 0.0022 |
Use of corticosteroid (%) | 90 | 60 | 0.0007 |
Use of biologics (%) | 10 | 8 | 0.7414 |